Cargando…
Study of SOX combined with intraperitoneal high‐dose paclitaxel in gastric cancer with synchronous peritoneal metastasis: A phase II single‐arm clinical trial
BACKGROUND: Intraperitoneal paclitaxel is proved to be efficient for peritoneal metastasis of gastric cancer. It remains uncertain the efficacy and safety of the triplets regimen which combined intraperitoneal high‐dose paclitaxel with systemic SOX in gastric cancer patients with peritoneal metastas...
Autores principales: | Tu, Li, Zhang, Weihan, Ni, Lu, Xu, Zihan, Yang, Kun, Gou, Hongfeng, Zhu, Qing, Liu, Ming, Yang, Yu, Hu, Jiankun, Qiu, Meng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972103/ https://www.ncbi.nlm.nih.gov/pubmed/36161282 http://dx.doi.org/10.1002/cam4.5277 |
Ejemplares similares
-
Multicenter Retrospective Analysis of Intraperitoneal Paclitaxel and Systemic Chemotherapy for Advanced Gastric Cancer with Peritoneal Metastasis
por: Kim, Dong-Wook, et al.
Publicado: (2020) -
Oxaliplatin plus S-1 with intraperitoneal paclitaxel for the treatment of Chinese advanced gastric cancer with peritoneal metastases
por: Shi, Min, et al.
Publicado: (2021) -
Intraperitoneal Paclitaxel Combined with S-1 Plus Oxaliplatin for Advanced Gastric Cancer with Peritoneal Metastasis: a Phase I Study
por: Kim, Dong-Wook, et al.
Publicado: (2021) -
A randomized phase II trial comparing capecitabine with oxaliplatin or docetaxel as first-line treatment in advanced gastric and gastroesophageal adenocarcinomas
por: Ni, Lu, et al.
Publicado: (2021) -
Phase I/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis
por: Yamada, S., et al.
Publicado: (2020)